Microchip Technology Raises Q3 Sales Guidance Significantly, Citing Broad Market Recovery
Summary
Microchip Technology announced it expects Q3 fiscal 2026 net sales to be approximately $1.185 billion, exceeding its original guidance and indicating a broad-based market recovery.
Key Events
-
Q3 Fiscal 2026 Net Sales Guidance Raised
Microchip Technology now expects net sales for the third quarter of fiscal 2026 to be approximately $1.185 billion, which is well above its original guidance range of $1.109 billion to $1.149 billion.
-
Broad-Based Market Recovery
The company is experiencing a broad-based recovery across most end markets, driven by progress in inventory correction for both distribution and direct customers, and new customer designs moving to production.
-
Strong Bookings and Improved Backlog
Bookings activity was very strong in the December quarter, and the starting backlog for the March quarter is significantly better than that for the December quarter.
-
Operational Improvements and Positive Outlook
Substantial progress has been made on the nine-point recovery plan, including a significant reduction in internal inventory and preparations to ramp factories in the March quarter, leading to an optimistic outlook for calendar year 2026.
Analysis
The upward revision of Q3 fiscal 2026 net sales guidance, significantly above the previous range, signals stronger-than-expected performance and a positive shift in market conditions for Microchip Technology. The CEO's commentary highlights a broad-based recovery, successful inventory correction, strong bookings, and preparations to ramp factory production, all of which point to improving operational health and a positive outlook for calendar year 2026. This update suggests that the company's nine-point recovery plan is yielding tangible results, which could positively impact investor sentiment and future earnings expectations.
At the time of this filing, MCHP was trading at $70.79 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $36.2B. The 52-week trading range was $34.13 to $77.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.